Metraipolis › archive › dc_258a0217e2c3

Application of nafamostat mesylate in 5 cases of extracorporeal carbon dioxide removal combined with continuous renal replacement therapy — Europe PMC PMID:40969946

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40969946
DOI
10.3389/fphar.2025.1592562
License (as archived)
solo-consultazione
Archived
2026-11-10T03:43:47.689Z
SHA-256 of the archived text
06300bd99c6a64da1736e6d8b6e04a4274f2cda666d40059bb2646c9280800fc
Stable URL of this page
https://metraipolis.com/documento/dc_258a0217e2c3

How to cite

Application of nafamostat mesylate in 5 cases of extracorporeal carbon dioxide removal combined with continuous renal replacement therapy — Europe PMC PMID:40969946 — Europe PMC (en), https://europepmc.org/article/MED/40969946 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_258a0217e2c3 (Metraipolis archive dc_258a0217e2c3, sha256 06300bd99c6a64da1736e6d8b6e04a4274f2cda666d40059bb2646c9280800fc)
BibTeX
@misc{dc258a0217e2c3,
  title = {Application of nafamostat mesylate in 5 cases of extracorporeal carbon dioxide removal combined with continuous renal replacement therapy — Europe PMC PMID:40969946},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40969946},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_258a0217e2c3; sha256 06300bd99c6a64da1736e6d8b6e04a4274f2cda666d40059bb2646c9280800fc},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40969946. Agents can read the archived copy with the MCP tool read_document.